In the past several years, clinical trials from several institutions to evaluate CAR-modified T cell (CAR-T cell) therapy for B cell malignancies including B cell acute lymphoblastic leukemia (B-ALL), B cell non-Hodgkin’s lymphoma (B-NHL), chronic lymphocytic leukemia (CLL), and Hodgkin’s lymphoma (HL) have demonstrated promising outcomes by targeting CD19 [5–13], CD20 [14], or CD30 [15], where mostly compelling success has been achieved in CD19-specific CAR-T cells for B-ALL with similar high complete remission (CR) rates of 70~94% [5–8, 12]. The gene discussed is TNFRSF8; the disease is B-cell chronic lymphocytic leukemia.